The Experts below are selected from a list of 161712 Experts worldwide ranked by ideXlab platform
Kelly L Covello - One of the best experts on this subject based on the ideXlab platform.
-
a phase i dose escalation and cohort expansion study of lirilumab anti kir bms 986015 administered in combination with nivolumab anti pd 1 bms 936558 ono 4538 in patients pts with advanced refractory solid tumors
Journal of Clinical Oncology, 2013Co-Authors: Rachel E Sanborn, William H Sharfman, Neil H Segal, Stephen F Hodi, Jedd D Wolchok, Walter J Urba, Bernard A Fox, Suzanne L Topalian, Drew M Pardoll, Kelly L CovelloAbstract:TPS3110 Background: Immune checkpoint blockade represents a novel form of cancer immunotherapy. Killer cell Immunoglobulin-Like Receptor (KIR) and programmed death-1 (PD-1) are immune Receptors tha...
-
a phase i dose escalation and cohort expansion study of lirilumab anti kir bms 986015 administered in combination with nivolumab anti pd 1 bms 936558 ono 4538 in patients pts with advanced refractory solid tumors
Journal of Clinical Oncology, 2013Co-Authors: Rachel E Sanborn, William H Sharfman, Neil H Segal, Stephen F Hodi, Jedd D Wolchok, Walter J Urba, Bernard A Fox, Suzanne L Topalian, Drew M Pardoll, Kelly L CovelloAbstract:TPS3110 Background: Immune checkpoint blockade represents a novel form of cancer immunotherapy. Killer cell Immunoglobulin-Like Receptor (KIR) and programmed death-1 (PD-1) are immune Receptors that down-regulate NK and T cell activity, respectively. Lirilumab, an anti-KIR antibody that potentiates innate immunity, has demonstrated modest side effects in a phase I monotherapy trial. Nivolumab, a PD-1 Receptor blocking antibody that potentiates adaptive immunity, has shown clinical activity with various solid tumors in phase I and II trials. We hypothesized that coordinate modulation of innate and adaptive immunity with anti-KIR and anti-PD-1 antibodies could achieve more favorable biologic and clinical activity than either agent alone. Here, we describe a phase I study of lirilumab plus nivolumab in pts with advanced solid tumors, the first collaborative clinical trial being conducted by the International Immuno-Oncology Network (II-ON). Methods: This study will be performed in two parts and enroll approx...
Rachel E Sanborn - One of the best experts on this subject based on the ideXlab platform.
-
a phase i dose escalation and cohort expansion study of lirilumab anti kir bms 986015 in combination with nivolumab anti pd 1 bms 936558 ono 4538 in advanced solid tumors
Journal of Clinical Oncology, 2014Co-Authors: Neil H Segal, Rachel E Sanborn, Stephen F Hodi, Jedd D Wolchok, Walter J Urba, Bernard A Fox, Suzanne L Topalian, Drew M Pardoll, Thomas F Gajewski, Georgia KolliaAbstract:TPS3115 Background: Killer cell Immunoglobulin-Like Receptor (KIR) and programmed death-1 (PD-1) are immune Receptors that downregulate natural killer (NK) cell and T-cell activity, respectively. Immune checkpoint blockade is emerging as a novel form of cancer immunotherapy. Lirilumab, an anti-KIR antibody, potentiates NK activity and innate immunity, with only modest side effects (mostly grade 1 or 2) in a phase I monotherapy trial. Nivolumab, a fully human IgG4 PD-1 immune checkpoint inhibitor antibody, potentiates T-cell activity and adaptive immunity, and has shown durable activity in various solid tumors, including melanoma (MEL), kidney cancer and non-small cell lung cancer (NSCLC). We hypothesize that simultaneous KIR and PD-1 blockade will enhance innate and adaptive immunity, resulting in greater clinical activity than with either agent alone. We describe a phase I study of lirilumab and nivolumab in patients (pts) with advanced solid tumors, the first collaborative trial conducted by the Interna...
-
a phase i dose escalation and cohort expansion study of lirilumab anti kir bms 986015 administered in combination with nivolumab anti pd 1 bms 936558 ono 4538 in patients pts with advanced refractory solid tumors
Journal of Clinical Oncology, 2013Co-Authors: Rachel E Sanborn, William H Sharfman, Neil H Segal, Stephen F Hodi, Jedd D Wolchok, Walter J Urba, Bernard A Fox, Suzanne L Topalian, Drew M Pardoll, Kelly L CovelloAbstract:TPS3110 Background: Immune checkpoint blockade represents a novel form of cancer immunotherapy. Killer cell Immunoglobulin-Like Receptor (KIR) and programmed death-1 (PD-1) are immune Receptors tha...
-
a phase i dose escalation and cohort expansion study of lirilumab anti kir bms 986015 administered in combination with nivolumab anti pd 1 bms 936558 ono 4538 in patients pts with advanced refractory solid tumors
Journal of Clinical Oncology, 2013Co-Authors: Rachel E Sanborn, William H Sharfman, Neil H Segal, Stephen F Hodi, Jedd D Wolchok, Walter J Urba, Bernard A Fox, Suzanne L Topalian, Drew M Pardoll, Kelly L CovelloAbstract:TPS3110 Background: Immune checkpoint blockade represents a novel form of cancer immunotherapy. Killer cell Immunoglobulin-Like Receptor (KIR) and programmed death-1 (PD-1) are immune Receptors that down-regulate NK and T cell activity, respectively. Lirilumab, an anti-KIR antibody that potentiates innate immunity, has demonstrated modest side effects in a phase I monotherapy trial. Nivolumab, a PD-1 Receptor blocking antibody that potentiates adaptive immunity, has shown clinical activity with various solid tumors in phase I and II trials. We hypothesized that coordinate modulation of innate and adaptive immunity with anti-KIR and anti-PD-1 antibodies could achieve more favorable biologic and clinical activity than either agent alone. Here, we describe a phase I study of lirilumab plus nivolumab in pts with advanced solid tumors, the first collaborative clinical trial being conducted by the International Immuno-Oncology Network (II-ON). Methods: This study will be performed in two parts and enroll approx...
Neil H Segal - One of the best experts on this subject based on the ideXlab platform.
-
a phase i dose escalation and cohort expansion study of lirilumab anti kir bms 986015 in combination with nivolumab anti pd 1 bms 936558 ono 4538 in advanced solid tumors
Journal of Clinical Oncology, 2014Co-Authors: Neil H Segal, Rachel E Sanborn, Stephen F Hodi, Jedd D Wolchok, Walter J Urba, Bernard A Fox, Suzanne L Topalian, Drew M Pardoll, Thomas F Gajewski, Georgia KolliaAbstract:TPS3115 Background: Killer cell Immunoglobulin-Like Receptor (KIR) and programmed death-1 (PD-1) are immune Receptors that downregulate natural killer (NK) cell and T-cell activity, respectively. Immune checkpoint blockade is emerging as a novel form of cancer immunotherapy. Lirilumab, an anti-KIR antibody, potentiates NK activity and innate immunity, with only modest side effects (mostly grade 1 or 2) in a phase I monotherapy trial. Nivolumab, a fully human IgG4 PD-1 immune checkpoint inhibitor antibody, potentiates T-cell activity and adaptive immunity, and has shown durable activity in various solid tumors, including melanoma (MEL), kidney cancer and non-small cell lung cancer (NSCLC). We hypothesize that simultaneous KIR and PD-1 blockade will enhance innate and adaptive immunity, resulting in greater clinical activity than with either agent alone. We describe a phase I study of lirilumab and nivolumab in patients (pts) with advanced solid tumors, the first collaborative trial conducted by the Interna...
-
a phase i dose escalation and cohort expansion study of lirilumab anti kir bms 986015 administered in combination with nivolumab anti pd 1 bms 936558 ono 4538 in patients pts with advanced refractory solid tumors
Journal of Clinical Oncology, 2013Co-Authors: Rachel E Sanborn, William H Sharfman, Neil H Segal, Stephen F Hodi, Jedd D Wolchok, Walter J Urba, Bernard A Fox, Suzanne L Topalian, Drew M Pardoll, Kelly L CovelloAbstract:TPS3110 Background: Immune checkpoint blockade represents a novel form of cancer immunotherapy. Killer cell Immunoglobulin-Like Receptor (KIR) and programmed death-1 (PD-1) are immune Receptors tha...
-
a phase i dose escalation and cohort expansion study of lirilumab anti kir bms 986015 administered in combination with nivolumab anti pd 1 bms 936558 ono 4538 in patients pts with advanced refractory solid tumors
Journal of Clinical Oncology, 2013Co-Authors: Rachel E Sanborn, William H Sharfman, Neil H Segal, Stephen F Hodi, Jedd D Wolchok, Walter J Urba, Bernard A Fox, Suzanne L Topalian, Drew M Pardoll, Kelly L CovelloAbstract:TPS3110 Background: Immune checkpoint blockade represents a novel form of cancer immunotherapy. Killer cell Immunoglobulin-Like Receptor (KIR) and programmed death-1 (PD-1) are immune Receptors that down-regulate NK and T cell activity, respectively. Lirilumab, an anti-KIR antibody that potentiates innate immunity, has demonstrated modest side effects in a phase I monotherapy trial. Nivolumab, a PD-1 Receptor blocking antibody that potentiates adaptive immunity, has shown clinical activity with various solid tumors in phase I and II trials. We hypothesized that coordinate modulation of innate and adaptive immunity with anti-KIR and anti-PD-1 antibodies could achieve more favorable biologic and clinical activity than either agent alone. Here, we describe a phase I study of lirilumab plus nivolumab in pts with advanced solid tumors, the first collaborative clinical trial being conducted by the International Immuno-Oncology Network (II-ON). Methods: This study will be performed in two parts and enroll approx...
Jedd D Wolchok - One of the best experts on this subject based on the ideXlab platform.
-
a phase i dose escalation and cohort expansion study of lirilumab anti kir bms 986015 in combination with nivolumab anti pd 1 bms 936558 ono 4538 in advanced solid tumors
Journal of Clinical Oncology, 2014Co-Authors: Neil H Segal, Rachel E Sanborn, Stephen F Hodi, Jedd D Wolchok, Walter J Urba, Bernard A Fox, Suzanne L Topalian, Drew M Pardoll, Thomas F Gajewski, Georgia KolliaAbstract:TPS3115 Background: Killer cell Immunoglobulin-Like Receptor (KIR) and programmed death-1 (PD-1) are immune Receptors that downregulate natural killer (NK) cell and T-cell activity, respectively. Immune checkpoint blockade is emerging as a novel form of cancer immunotherapy. Lirilumab, an anti-KIR antibody, potentiates NK activity and innate immunity, with only modest side effects (mostly grade 1 or 2) in a phase I monotherapy trial. Nivolumab, a fully human IgG4 PD-1 immune checkpoint inhibitor antibody, potentiates T-cell activity and adaptive immunity, and has shown durable activity in various solid tumors, including melanoma (MEL), kidney cancer and non-small cell lung cancer (NSCLC). We hypothesize that simultaneous KIR and PD-1 blockade will enhance innate and adaptive immunity, resulting in greater clinical activity than with either agent alone. We describe a phase I study of lirilumab and nivolumab in patients (pts) with advanced solid tumors, the first collaborative trial conducted by the Interna...
-
a phase i dose escalation and cohort expansion study of lirilumab anti kir bms 986015 administered in combination with nivolumab anti pd 1 bms 936558 ono 4538 in patients pts with advanced refractory solid tumors
Journal of Clinical Oncology, 2013Co-Authors: Rachel E Sanborn, William H Sharfman, Neil H Segal, Stephen F Hodi, Jedd D Wolchok, Walter J Urba, Bernard A Fox, Suzanne L Topalian, Drew M Pardoll, Kelly L CovelloAbstract:TPS3110 Background: Immune checkpoint blockade represents a novel form of cancer immunotherapy. Killer cell Immunoglobulin-Like Receptor (KIR) and programmed death-1 (PD-1) are immune Receptors tha...
-
a phase i dose escalation and cohort expansion study of lirilumab anti kir bms 986015 administered in combination with nivolumab anti pd 1 bms 936558 ono 4538 in patients pts with advanced refractory solid tumors
Journal of Clinical Oncology, 2013Co-Authors: Rachel E Sanborn, William H Sharfman, Neil H Segal, Stephen F Hodi, Jedd D Wolchok, Walter J Urba, Bernard A Fox, Suzanne L Topalian, Drew M Pardoll, Kelly L CovelloAbstract:TPS3110 Background: Immune checkpoint blockade represents a novel form of cancer immunotherapy. Killer cell Immunoglobulin-Like Receptor (KIR) and programmed death-1 (PD-1) are immune Receptors that down-regulate NK and T cell activity, respectively. Lirilumab, an anti-KIR antibody that potentiates innate immunity, has demonstrated modest side effects in a phase I monotherapy trial. Nivolumab, a PD-1 Receptor blocking antibody that potentiates adaptive immunity, has shown clinical activity with various solid tumors in phase I and II trials. We hypothesized that coordinate modulation of innate and adaptive immunity with anti-KIR and anti-PD-1 antibodies could achieve more favorable biologic and clinical activity than either agent alone. Here, we describe a phase I study of lirilumab plus nivolumab in pts with advanced solid tumors, the first collaborative clinical trial being conducted by the International Immuno-Oncology Network (II-ON). Methods: This study will be performed in two parts and enroll approx...
Walter J Urba - One of the best experts on this subject based on the ideXlab platform.
-
a phase i dose escalation and cohort expansion study of lirilumab anti kir bms 986015 in combination with nivolumab anti pd 1 bms 936558 ono 4538 in advanced solid tumors
Journal of Clinical Oncology, 2014Co-Authors: Neil H Segal, Rachel E Sanborn, Stephen F Hodi, Jedd D Wolchok, Walter J Urba, Bernard A Fox, Suzanne L Topalian, Drew M Pardoll, Thomas F Gajewski, Georgia KolliaAbstract:TPS3115 Background: Killer cell Immunoglobulin-Like Receptor (KIR) and programmed death-1 (PD-1) are immune Receptors that downregulate natural killer (NK) cell and T-cell activity, respectively. Immune checkpoint blockade is emerging as a novel form of cancer immunotherapy. Lirilumab, an anti-KIR antibody, potentiates NK activity and innate immunity, with only modest side effects (mostly grade 1 or 2) in a phase I monotherapy trial. Nivolumab, a fully human IgG4 PD-1 immune checkpoint inhibitor antibody, potentiates T-cell activity and adaptive immunity, and has shown durable activity in various solid tumors, including melanoma (MEL), kidney cancer and non-small cell lung cancer (NSCLC). We hypothesize that simultaneous KIR and PD-1 blockade will enhance innate and adaptive immunity, resulting in greater clinical activity than with either agent alone. We describe a phase I study of lirilumab and nivolumab in patients (pts) with advanced solid tumors, the first collaborative trial conducted by the Interna...
-
a phase i dose escalation and cohort expansion study of lirilumab anti kir bms 986015 administered in combination with nivolumab anti pd 1 bms 936558 ono 4538 in patients pts with advanced refractory solid tumors
Journal of Clinical Oncology, 2013Co-Authors: Rachel E Sanborn, William H Sharfman, Neil H Segal, Stephen F Hodi, Jedd D Wolchok, Walter J Urba, Bernard A Fox, Suzanne L Topalian, Drew M Pardoll, Kelly L CovelloAbstract:TPS3110 Background: Immune checkpoint blockade represents a novel form of cancer immunotherapy. Killer cell Immunoglobulin-Like Receptor (KIR) and programmed death-1 (PD-1) are immune Receptors tha...
-
a phase i dose escalation and cohort expansion study of lirilumab anti kir bms 986015 administered in combination with nivolumab anti pd 1 bms 936558 ono 4538 in patients pts with advanced refractory solid tumors
Journal of Clinical Oncology, 2013Co-Authors: Rachel E Sanborn, William H Sharfman, Neil H Segal, Stephen F Hodi, Jedd D Wolchok, Walter J Urba, Bernard A Fox, Suzanne L Topalian, Drew M Pardoll, Kelly L CovelloAbstract:TPS3110 Background: Immune checkpoint blockade represents a novel form of cancer immunotherapy. Killer cell Immunoglobulin-Like Receptor (KIR) and programmed death-1 (PD-1) are immune Receptors that down-regulate NK and T cell activity, respectively. Lirilumab, an anti-KIR antibody that potentiates innate immunity, has demonstrated modest side effects in a phase I monotherapy trial. Nivolumab, a PD-1 Receptor blocking antibody that potentiates adaptive immunity, has shown clinical activity with various solid tumors in phase I and II trials. We hypothesized that coordinate modulation of innate and adaptive immunity with anti-KIR and anti-PD-1 antibodies could achieve more favorable biologic and clinical activity than either agent alone. Here, we describe a phase I study of lirilumab plus nivolumab in pts with advanced solid tumors, the first collaborative clinical trial being conducted by the International Immuno-Oncology Network (II-ON). Methods: This study will be performed in two parts and enroll approx...
